HC Wainwright Issues Positive Forecast for Evaxion A/S (NASDAQ:EVAX) Stock Price

Evaxion A/S (NASDAQ:EVAX) had its target price upped by HC Wainwright from $14.00 to $16.00 in a report issued on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Wall Street Zen upgraded shares of Evaxion A/S to a “hold” rating in a research note on Friday, June 27th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $11.00.

Evaxion A/S Stock Up 37.3%

EVAX opened at $4.53 on Thursday. Evaxion A/S has a fifty-two week low of $1.20 and a fifty-two week high of $16.10. The company has a debt-to-equity ratio of 1.73, a current ratio of 3.42 and a quick ratio of 3.42. The firm’s fifty day moving average price is $2.92 and its two-hundred day moving average price is $2.31. The company has a market capitalization of $6.34 million, a P/E ratio of -3.43 and a beta of 0.14.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.26). Evaxion A/S had a negative return on equity of 319.52% and a negative net margin of 316.03%.The business had revenue of $0.04 million for the quarter. On average, analysts anticipate that Evaxion A/S will post -0.15 EPS for the current year.

Institutional Investors Weigh In On Evaxion A/S

An institutional investor recently raised its position in Evaxion A/S stock. Merck & Co. Inc. increased its stake in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) by 123.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,214,126 shares of the company’s stock after buying an additional 671,847 shares during the period. Evaxion A/S accounts for approximately 1.4% of Merck & Co. Inc.’s holdings, making the stock its 6th biggest holding. Merck & Co. Inc. owned about 86.54% of Evaxion A/S worth $2,246,000 as of its most recent SEC filing. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.